LYNDHURST, N.J., May 30 /PRNewswire-FirstCall/ -- Quest Diagnostics
Incorporated (NYSE: DGX), the leading provider of diagnostic testing,
information and services, announced today that it plans to complete its
previously announced acquisition of AmeriPath, Inc. on May 31, 2007. The
waiting period under the Hart-Scott-Rodino Antitrust Improvements Act expired
on May 29, 2007.
About AmeriPath
AmeriPath, a leading national provider of physician-based anatomic
pathology, dermatopathology and molecular diagnostic services to physicians,
hospitals, clinical laboratories and surgery centers, supports community-based
medicine by helping physicians provide excellent and effective care for their
patients. A team of sub-specialized pathologists and Ph.D. scientists provide
medical expertise, diagnostic quality, and personal consultation services.
AmeriPath's team of approximately 400 highly trained, board-certified
pathologists provide medical diagnostics services in outpatient laboratories
owned, operated and managed by AmeriPath, as well as in hospitals and
ambulatory surgical centers.
About Quest Diagnostics
Quest Diagnostics is the leading provider of diagnostic testing,
information and services that patients and doctors need to make better
healthcare decisions. The company offers the broadest access to diagnostic
testing services through its national network of laboratories and patient
service centers, and provides interpretive consultation through its extensive
medical and scientific staff. Quest Diagnostics is a pioneer in developing
innovative new diagnostic tests and advanced healthcare information technology
solutions that help improve patient care. Additional company information is
available at: www.questdiagnostics.com.
This communication contains certain forward-looking statements. These
forward-looking statements, which may include, but are not limited to,
statements concerning the proposed acquisition, are based on management's
current expectations and estimates and involve risks and uncertainties that
could cause actual results or outcomes to differ materially from those
contemplated by the forward-looking statements. Certain of these risks and
uncertainties may include, but are not limited to the risks and uncertainties
described in the Quest Diagnostics Incorporated 2006 Form 10-K and subsequent
filings.
SOURCE Quest Diagnostics Incorporated
-0- 05/30/2007
/CONTACT: Investors, Laure Park, +1-201-393-5030, or Media, Nancy
Fitzsimmons +1-201-393-5700 /
/Web site: http://www.questdiagnostics.com/
(DGX)
CO: Quest Diagnostics; AmeriPath
ST: Illinois
IN: HEA MTC CPR BIO
SU: TNM
JR-BS
-- NYW045 --
5988 05/30/2007 08:00 EDT http://www.prnewswire.com